Cresilon's TRAUMAGEL Receives Vizient's Innovative Technology Contract, Transforming Hemorrhage Control

Cresilon's TRAUMAGEL Receives prestigious Innovative Technology Contract from Vizient

Cresilon, a groundbreaking biotechnology company based in Brooklyn, has recently made headlines with the announcement that its hemostatic gel, TRAUMAGEL®, has received an Innovative Technology contract from Vizient®, recognized as the largest provider-driven performance improvement company in the U.S. This achievement highlights not only the effectiveness of TRAUMAGEL but also its potential to significantly enhance patient care in emergency situations.

What is TRAUMAGEL?

TRAUMAGEL is an innovative hemostatic gel that utilizes Cresilon's proprietary technology to provide rapid control of bleeding. It is notably the first gel available in a syringe designed specifically for traumatic hemorrhage, possessing the unique advantage of being flowable with U.S. FDA 510(k) clearance for temporary external use. TRAUMAGEL is supplied in a 30 mL sterile prefilled syringe, which allows for immediate application without any preparation, making it a critical tool in emergency medical settings.

The Significance of the Innovative Technology Contract

Vizient's Innovative Technology contracts are awarded based on thorough reviews conducted by hospital experts who evaluate new products that show promise in enhancing clinical care, patient safety, and the overall efficiency of healthcare operations. The contract serves as a recognition from Vizient's client-led councils, which have identified TRAUMAGEL as a unique product that could revolutionize standards of care for hemorrhage control.

Joe Landolina, CEO and co-founder of Cresilon, expressed the importance of this contract, stating, "Receiving the Innovative Technology contract from Vizient marks a significant milestone for Cresilon and underscores the positive clinical feedback we have gathered since the launch of TRAUMAGEL last year. We believe that this technology is setting a new standard for hemorrhage control, leading to increased adoption among healthcare professionals across the nation."

Impact on Healthcare

The contract awarded by Vizient facilitates broader access to this cutting-edge technology for licensed medical professionals. With TRAUMAGEL's demonstrated ability to control bleeding almost instantaneously, it has the potential to save lives in critical situations by improving the speed and effectiveness of trauma care.

Kelly Flaharty, associate vice president of contract operations for Vizient, noted, "After a careful review, our client-led council recognized that TRAUMAGEL provides a distinct advantage over existing products in the market. We are delighted to award this contract to Cresilon, enhancing the resources available to healthcare providers nationwide."

The Role of Vizient

Vizient operates with a diverse client base, including academic medical centers, community hospitals, and various healthcare networks. With an impressive annual purchasing volume exceeding $156 billion, Vizient's Innovative Technology Program plays a crucial role in evaluating and endorsing healthcare products that possess the capacity for significant innovation. The framework provided by Vizient allows products like TRAUMAGEL to reach the market outside the constraints of traditional bidding cycles, ensuring that healthcare providers can access advanced solutions swiftly.

About Cresilon

Founded in Brooklyn, Cresilon has carved out a niche in the biotechnology field by focusing on the development of hemostatic medical devices that utilize their proprietary hydrogel technology. Their commitment to revolutionizing trauma care through quick and effective bleeding control has positioned them at the forefront of the industry. Cresilon has received accolades, including recognition from Fast Company as one of the world's Most Innovative Companies, further validating its impact on healthcare.

In conclusion, the Innovative Technology contract awarded to Cresilon for TRAUMAGEL is not just a win for the company but a promising advancement in the healthcare landscape. As this innovative solution enhances the ability to manage traumatic bleeding, it underscores the importance of continued innovation in medical technologies aimed at saving lives.

For more information about Cresilon and its products, visit Cresilon's official website.